August 28, 2019 04:07 PM EDTUpdated August 29, 10:27 AM
Pharma

Am­gen’s leg­endary lawyer corps los­es a ma­jor court fight at­tempt­ing to quash PC­SK9 ri­val from Sanofi, Re­gen­eron

John Carroll

Editor & Founder

Sanofi and Re­gen­eron may be los­ing the bat­tle for sales of their PC­SK9 drug Pralu­ent in their fight against Am­gen’s Repatha for mar­ket share — but they just won a bad­ly need­ed vic­to­ry on the le­gal front.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times